Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Resistance to proteasome inhibitors and other targeted therapies in myeloma
Craig T. Wallington‐Beddoe, Magdalena Sobieraj‐Teague, Bryone J. Kuss, et al.
British Journal of Haematology (2018) Vol. 182, Iss. 1, pp. 11-28
Open Access | Times Cited: 99

Showing 26-50 of 99 citing articles:

An overview of multiple myeloma: A monoclonal plasma cell malignancy’s diagnosis, management, and treatment modalities
Maisa Siddiq Abduh
Saudi Journal of Biological Sciences (2023) Vol. 31, Iss. 2, pp. 103920-103920
Open Access | Times Cited: 12
Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment
María Matamala Montoya, Gijs J. J. van Slobbe, Jung‐Chin Chang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their Introduction
Paweł Tyrna, Grzegorz Procyk, Łukasz Szeleszczuk, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8949-8949
Open Access | Times Cited: 4
Retrospective Study to Compare Outcomes in 159 Patients Undergoing First Autologous Stem Cell Transplantation for Myeloma Treated with Melphalan 140 mg/m² or 200 mg/m²
Umut Yılmaz, Sukran Erdem, Deniz Özmen, et al.
Annals of Transplantation (2025) Vol. 30
Open Access
Inhibition of the FAD containing ER oxidoreductin 1 (Ero1) protein by EN-460 as a strategy for treatment of multiple myeloma
Karen E. Hayes, Paratchata Batsomboon, Wei-Chih Chen, et al.
Bioorganic & Medicinal Chemistry (2019) Vol. 27, Iss. 8, pp. 1479-1488
Open Access | Times Cited: 35
M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models
Michael P. Sanderson, Manja Friese‐Hamim, Gina Walter-Bausch, et al.
Molecular Cancer Therapeutics (2021) Vol. 20, Iss. 8, pp. 1378-1387
Open Access | Times Cited: 24
NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma
Xi Huang, Wen Cao, Shunnan Yao, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 3
Open Access | Times Cited: 17
Proteasome Inhibitors in Multiple Myeloma
Constantine S. Mitsiades
Hematology/Oncology Clinics of North America (2024) Vol. 38, Iss. 2, pp. 321-336
Closed Access | Times Cited: 3
Targeting the ribosome to treat multiple myeloma
Kylee Maclachlan, Kezia Gitareja, Jian Kang, et al.
Deleted Journal (2024) Vol. 32, Iss. 1, pp. 200771-200771
Open Access | Times Cited: 3
Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines
Mara N. Zeissig, D. Hewett, Krzysztof M. Mrozik, et al.
Leukemia Research (2024) Vol. 139, pp. 107469-107469
Open Access | Times Cited: 3
Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance
Jin Yang, Yan‐Cheng Yu, Zixuan Wang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116435-116435
Closed Access | Times Cited: 3
Threonine and tyrosine kinase promotes multiple myeloma progression by regulating regucalcin expression
Xiaofeng Zhu, Zuxi Feng, Xiaohuan Peng, et al.
Experimental Cell Research (2025), pp. 114454-114454
Open Access
Therapeutic Target Discovery for Multiple Myeloma: Identifying Druggable Genes via Mendelian Randomization
Shijun Jiang, Fengjuan Fan, Qun Li, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 885-885
Open Access
ZMYND8 Reads H3K36me2 to Activate CEBPE Transcription and Suppress Multiple Myeloma Progression through the Inhibition of Adaptive UPR Pathways
Jiaxuan Xu, Xiaoqing Dong, Yue Peng, et al.
Advanced Science (2025)
Open Access
Knockdown of RNF6 inhibits gastric cancer cell growth by suppressing STAT3 signaling
Ziming Huang, Yong Cai, Chenchen Yang, et al.
OncoTargets and Therapy (2018) Vol. Volume 11, pp. 6579-6587
Open Access | Times Cited: 29
The Proteasome System in Health and Disease
Olivier Coux, Barbara A. Zieba, Silke Meiners
Advances in experimental medicine and biology (2020), pp. 55-100
Closed Access | Times Cited: 24
The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma
Lisa Crawford, David Campbell, Jonathan J. Morgan, et al.
Oncogene (2020) Vol. 39, Iss. 27, pp. 5001-5014
Open Access | Times Cited: 24
TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy
Jing Chen, Wen Cao, Xi Huang, et al.
Blood Advances (2023) Vol. 7, Iss. 19, pp. 5752-5770
Open Access | Times Cited: 8
NCX1/Ca2+ promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NFκB signaling pathway
Tingting Li, Pingping Xiao, Dongbiao Qiu, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
MYC inhibitors in multiple myeloma
Sandra Martínez-Martín, Laura Soucek
Cancer Drug Resistance (2021)
Open Access | Times Cited: 18
Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML
Rareş Drulă, Sabina Iluta, Diana Gulei, et al.
Blood Reviews (2022) Vol. 56, pp. 100971-100971
Open Access | Times Cited: 14
Identification and validation of a novel cuproptosis-related gene signature in multiple myeloma
Bingxin Zhang, Quanqiang Wang, Tianyu Zhang, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 7
NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma
Chia‐Hung Yen, Hui‐Hua Hsiao
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 11, pp. 3503-3503
Open Access | Times Cited: 21
Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib
Silvia Sevilla‐Movilla, Nohemí Arellano‐Sánchez, Mónica Martínez‐Moreno, et al.
The Journal of Pathology (2020) Vol. 252, Iss. 1, pp. 29-40
Open Access | Times Cited: 20
ROS Overproduction Sensitises Myeloma Cells to Bortezomib-Induced Apoptosis and Alleviates Tumour Microenvironment-Mediated Cell Resistance
Mélody Caillot, Florence Zylbersztejn, Elsa Maître, et al.
Cells (2020) Vol. 9, Iss. 11, pp. 2357-2357
Open Access | Times Cited: 20

Scroll to top